Jay Rajadas’ Post

Check out our new review in Blood! Everything you ever wanted to know about heparan sulfates and heparan sulfate proteoglycans in hematopoiesis! https://lnkd.in/e7yABCwA

New Article: Activation of the insulin receptor by insulin-like growth factor 2 IGF2 has a distinct binding affinity for two insulin receptor (IR) isoforms and mimics insulin’s function. Here, the authors present the activation mechanism of IR by IGF2 and reveal the molecular basis for IGF2’s different affinity for two IR isoforms. https://lnkd.in/gjNZazwr

The zona occludens protein ZO-2 links transmembrane junctional proteins to the actin cytoskeleton, thus making the cellular network visible. Our Image of the Month shows an indirect immunostaining of MDCK cells using Tight junction protein ZO-2 antibody (cat. no. 504 005, red) and DAPI (blue). https://lnkd.in/et4VT24A #antibodies #immunfluorecence #imageofthemonth

At the ongoing American Society of Clinical Oncology (ASCO) 2024 conference, Agenus presented a novel analysis from the Phase Ib trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM). Botensilimab is a multifunctional Fc-enhanced anti–CTLA–4 agent that has been shown to enhance T-cell priming, expansion, and memory, as well as increase the frequency of antigen-presenting cells and deplete regulatory T cells. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage! https://lnkd.in/guj-UxfA #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

In January 2024, Slamon et al. published the final overall survival (OS) analysis for the PALMOA-2 trial of first-line non-steroidal aromatase inhibitor (NSAI) and palbociclib. The results confirm what had been reported for a few years: palbociclib does not confer a statistically significant OS benefit over placebo. Because of these data, is this the end of palbociclib in the advanced setting? Read on here: https://lnkd.in/dSvPnyTz

CD3 and B-cell maturation antigen (BCMA)–bispecific antibody Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus Need for long-term follow-up and controlled trial, but an encouraging signal. https://lnkd.in/etScpqdY

Glycosylation is the ultimate level of molecular complexity and we know very little about it... For example, even the location of IgG sialylation is currently actively debated, with a number of papers claiming this mostly happens after secretion from the plasma cell. In this meticulous study performed in collaboration with Falk Nimmerjahn and Anja Lux we provide evidence to the contrary and show that sialylation happens in the B cell before secretion. At least in mouse and in the absence of major inflammatory events. https://lnkd.in/dnA_6666

We're excited to be heading to Australia to participate in the Save Our Sons Duchenne Foundation 2024 National Duchenne Conference. We will have a booth to share more about our lead drug candidate, SAT-3247, and our Phase 1 clinical trial. SAT-3247 is an oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in #Duchenne #musculardystrophy and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status. Learn more about the conference here: https://lnkd.in/gFb_qdiU #raredisease #rarediseases #smallmolecule #regenmed #regenerativemedicine #clinicaltrials

Our latest review on Neuropilin-1 was published today in Biochemical Society Transactions. If you want to know about the fascinating role of NRP1 in endothelial cells in regulating TGFbeta signalling and the response to shear stress check it out! https://lnkd.in/eP5m3ysX

Curious about the immunmodulatory functions of the chemokine receptor ACKR3 (CXCR7) within the supporting cells of the olfactory epithelium? Read our latest publication: